Context Therapeutics Inc (CNTX)
Context Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for solid tumors. Its lead candidate, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody designed to direct T-cell activity toward cancer cells that express CLDN6. The company also has a collaboration and licensing agreement with Integral Molecular, Inc. related to development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. The company’s common stock trades on the NASDAQ under the ticker CNTX.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CNTX
|
$0.72
|
14.5% Upside
|
Fair
|
$5.38
|
757.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.4x
|
1.1x
|
—
|
56.598 M
|
3.362 M
|
0.5%
|
46.6%
|
0.4
|
—
|
81.6%
|
